Dimitris Moulavasilis – Group CEO, M42
Healthcare systems across the world continue to struggle with fragmentation, rising costs and reactive models of care that intervene too late. Dimitris Moulavasilis, Group CEO of M42, outlines how an…
The aim of the Dutch Clinical Trial Foundation, DCTF in short, is to improve the environment for clinical research in the Netherlands. Its task is to bring together the most important stakeholders to collectively discuss obstacles in the field of clinical research, and propose solutions. The role of the DCTF is a coordinating one, as a facilitating platform.
The DCTF Annual Conference is an important event, offering everyone active in the field clinical research to come together and discuss actual topics. Examples of collaboration, initiated by DCTF are the ‘MasterPlan Optimization of Clinical Research Preparation’, the standardized Patient Information Form, a uniform insurance for all (mono center and multi center) clinical studies and the standardized Clinical Trial Agreement.
The public role of DCTF is growing. In the next two years, DCTF will ensure the practical implementation of the new European Clinical Trial Regulation by informing and training everyone who has to work with this Directive, now and in the future. The platform will define and standardize the ideal review process, in which the new Regulation will be implemented.
This will positively contribute to DCTF’s ambition: optimizing the attractiveness of The Netherlands as a clinical research country, maintaining the international role in the development of drugs, vaccines and medical devices, but also playing a leading role in clinical research in a broader sense – in order to improve Dutch healthcare as a benefit for patients.
The DCTF was realized through cooperation of various parties. Representatives of these parties are also part of the General Board of the DCTF. These parties represent the university medical centers, government, contract research organizations, pharmaceutical industry, medical ethics committee, patients and others.
Contact details
Dutch Clinical Trial Foundation
Kuipersweg 2T
3449 JA Woerden, The Netherlands
Phone: 0031 348 489323
e-mail: secretariaat@dctf.nl
website: www.dctf.nl
Office manager: Ilse van der Woude
Healthcare systems across the world continue to struggle with fragmentation, rising costs and reactive models of care that intervene too late. Dimitris Moulavasilis, Group CEO of M42, outlines how an…
Complementing the Lyon region’s strong industrial footprint is a dense network of hospital facilities, only bettered by Paris on the national level. Across 13 hospitals in the Hospices Civils de…
Orla Cloak, CEO of Minaris, explains how the organisation. was formed by integrating Minaris Regenerative Medicine, a dedicated cell and gene therapy (CGT) CDMO, and WuXi Advanced Therapies, which brought…
Taiwan’s clinical research ecosystem has evolved rapidly in recent years, reflecting Asia’s growing role in global drug development. Samuel Su, Founder and CEO of Bestat Pharmaservices, discusses how the organisation…
Frank Bedu‑Addo shares his journey from scientist to co‑founder and CEO of PDS Biotechnology. He highlights promising progress across PDS’s oncology pipeline, including strategic decisions that have helped improve antitumor…
This week’s China healthcare highlights from PharmaBoardroom content partner Selesta include Trinomab preparing for a STAR Market IPO to raise RMB 1.5 billion for its monoclonal antibody portfolio, including first-in-class…
Lyon – recently announced as the host of BIO-Europe Spring 2027 – has long played a vital role in global health and, in 2026, it stands as one of Europe’s…
For decades, the Middle East has faced a disproportionately high burden of rare genetic disorders, fuelled both by deep-rooted cultural practices and an overreliance on Western genomic data. Fast forward…
Suzhou’s bioBAY has emerged as one of China’s most dynamic biotechnology clusters, bringing together hundreds of biotech and medtech companies within an ecosystem designed to support the full innovation cycle,…
Lyon’s leading biotechs have caught the eye of global pharma in recent years, with two major acquisitions attesting to the quality and sophistication of the ecosystem and laying a path…
Bringing together clinical scale, academic depth, and a strong engineering mindset, China Medical University Hospital has positioned itself as more than a care provider. In this interview, Dr Der-Yang Cho,…
Paul Kim, a leading FDA attorney and policy expert formerly at both the FDA and the US Congress, discusses the current shifts within the American life sciences and regulatory landscape.…
Tanya Carro details Duchesnay Pharmaceutical Group’s organic expansion from its women’s health core into rare diseases and generics. Operating across three geographic pillars, the privately held firm leverages Canadian pricing…
Promoted to General Manager of Moderna Taiwan in 2024, Wenchi Liu brings over 20 years of pharmaceutical industry experience spanning commercial strategy and operations. Since joining Moderna in 2023, she…
Christine Baeder, President of USA and LATAM at Apotex, discusses the company’s evolution following private equity investment, its Generics Plus strategy, and the critical role of the US market. She…
Professor Chak-sing Lau, BBS, JP, is Vice-President & Pro-Vice-Chancellor (Health) and Dean of Medicine at The University of Hong Kong (HKU). He leads HKU’s Li Ka Shing Faculty of Medicine…
Craig Martin, CEO of the Orphan Therapeutics Accelerator (OTXL), discusses the urgent need for a new business model to rescue abandoned clinical-stage programs in the rare disease sector. He details…
Sabrina Chan, Senior Executive at HKAPI, highlights progress in Hong Kong’s biomedical ambitions, including establishing an independent regulator, expanding clinical trial capacity via the Greater Bay Area Clinical Trial Institute…
Biotechnology in Taiwan is no longer a future aspiration, but an industrial system deliberately built for global relevance. In this conversation, the Chairman and CEO of the Development Centre for…
Following our conversation with CEO Lance Yuen on CK Life Sciences’ strategic direction, Chief Scientific Officer Melvin Toh now takes us inside the scientific engine driving that vision forward. He…
The Auvergne-Rhône-Alpes region, with Lyon at its heart, is France’s industrial heartland. Hosting over 500,000 manufacturing and manufacturing-related jobs, AURA is also the nation’s top destination the production of biologics,…
Dr Chen-Yu Cheng, founder and chairman at Formosa Laboratories & Pharmaceuticals, is leading a strategic transition from generic API manufacturing toward high- value CDMO services and innovative drug development. By…
Nasha Fitter, a tech entrepreneur and CEO of the FOXG1 Research Foundation, discusses the radical shift in drug development led by a new generation of sophisticated parent-entrepreneurs. Following her daughter’s…
Boston Scientific’s Dan Silver reflects on his global leadership journey and the evolution of the company’s presence in one of Asia’s most advanced healthcare systems. Silver discusses Boston Scientific’s growth…
Siegfried Gschliesser, co-founder and CEO of Anya Biopharm, has spent over two decades shaping the pharmaceutical landscape in Asia. Under his guidance, Anya has pioneered a proprietary oral peptide delivery platform,…
Writing in the March 2026 edition of DIA’s Global Forum magazine, PharmCube’s Juan Valencia looks back on a record year for drug approvals in China, and what it means for…
Sabrina Zimmerman, General Manager for Taiwan, Hong Kong, and Macau and APAC (excluding Japan) Portfolio Head at Biogen, shares her perspective on the company’s expanding presence in Asia and its…
Rainer Westermann offers a sobering take on Europe’s declining global status as both a source and recipient of biopharmaceutical innovation. He argues that the time for a paradigm shift in…
After 25 years at Genzyme and Sanofi, Chris Hwang joined a biotech startup in China in 2016 to develop advanced bioprocessing technologies that reduce cost of goods while maintaining reliable…
Kim Moran, SVP & Head of US Rare Disease at UCB, discusses how the company is building on its long-standing heritage in neurology to expand into rare and ultra-rare conditions.…
2026 could mark a turning point for biosimilar adoption in the US. By scrapping requirements for redundant clinical trials and pushing Congress to end the “Interchangeable” label, the FDA has…
Dr Cyrus Yang, CEO of Taiwan Bio Therapeutics, outlines how he transformed the company – founded in 2014 with proprietary MSC‑expansion technology – into a global innovator in cell and gene therapy.…
Developing effective CAR-T therapies for T-cell malignancies remains one of the most technically challenging frontiers in cell therapy. Dr Lin Yang of PersonGen Biotherapeutics discusses the company’s progress with its…
Asia is emerging as a critical frontier in oncology research, yet much of global drug development continues to overlook the region’s specific clinical needs. At the National Cancer Center Japan,…
In 2024, contract manufacturers WuXi Biologics and WuXi AppTec were catapulted into global consciousness as two of five Chinese service providers deemed a US national security threat in a draft…
Katherine Stueland, CEO of GeneDx, describes transforming the 26-year-old NIH spinout into a scalable, patient-focused business. Leveraging the Infinity database, strategic biopharma partnerships, AI-driven interpretation, and cost-efficient exome and genome…
European biotech’s recent struggles are well documented. Deep-pocketed investors with sufficient risk tolerance to fund potentially breakout companies are thin on the ground, and Europe is losing touch with both…
Founded by Dr Helen Yang and Dr Peter He, Oricell Therapeutics stands at the forefront of next-generation cell and gene therapy innovation. Built on a comprehensive platform that integrates antibody…
As Abu Dhabi translates strategy into execution, the focus turns from platform design to operational delivery. Albarah Elkhani, COO of Integrated Health Solutions at M42, details how large-scale genomics, clinical…
William Hait, Chief Scientific Advisor of the American Association for Cancer Research (AACR) and Chair of AACR’s Scientific Advisory Council, highlights the society’s position within the global oncology ecosystem as…
Healthcare is finally moving from a reactive “machine” to a proactive shield. In the latest issue of ISPOR’s Value & Outcomes Spotlight, Editor-in-Chief Zeba M. Khan, PhD, examines how Real-World…
See our Cookie Privacy Policy Here
